Published in J Hypertens on August 01, 2000
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A (2005) 1.85
The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart (2003) 1.63
Is B-type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the Heart and Soul Study. Am J Med (2004) 1.56
Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart (2002) 1.41
Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population-the CARLA study. PLoS One (2013) 0.97
Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer (2004) 0.87
NT-pro-BNP in obstructive sleep apnea syndrome is decreased by nasal continuous positive airway pressure. Clin Res Cardiol (2006) 0.87
Effects of ivabradine on allograft function and exercise performance in heart transplant recipients with permanent sinus tachycardia. Clin Res Cardiol (2008) 0.81
The relationship between adiponectin and left ventricular mass index varies with the risk of left ventricular hypertrophy. PLoS One (2013) 0.78
NT-proBNP Predicts Cardiovascular Death in the General Population Independent of Left Ventricular Mass and Function: Insights from a Large Population-Based Study with Long-Term Follow-Up. PLoS One (2016) 0.77
Natriuretic Peptides and Assessment of Cardiovascular Disease Risk in Asymptomatic Persons. Curr Cardiovasc Risk Rep (2010) 0.77
The role of brain natriuretic peptide in population screening. Heart Fail Rev (2003) 0.75
Addition of N-terminal pro-B-type natriuretic peptide levels to electrocardiography criteria for detection of left ventricular hypertrophy: the ARIRANG study. J Korean Med Sci (2015) 0.75
Plasma ProBNP Is Not a Specific Marker for Transient Myocardial Ischemia. J Clin Med Res (2015) 0.75
Relationship of extent and nature of dysfunctional myocardium to brain natriuretic peptide in patients with ischemic left ventricular dysfunction. Int J Cardiovasc Imaging (2005) 0.75
Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest (1991) 3.70
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation (1994) 3.63
The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med (1992) 3.53
Atrial natriuretic peptide elevation in congestive heart failure in the human. Science (1986) 3.37
Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet (1993) 3.34
Study of Health In Pomerania (SHIP): a health examination survey in an east German region: objectives and design. Soz Praventivmed (2001) 3.17
Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med (1994) 3.11
Large scale association analysis of novel genetic loci for coronary artery disease. Arterioscler Thromb Vasc Biol (2009) 2.71
Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J (2003) 2.40
Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension (1996) 2.37
Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation (1995) 2.25
Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol (1998) 2.24
Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med (1991) 2.22
Localization of a small genomic region associated with elevated ACE. Am J Hum Genet (2000) 2.13
Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation (1998) 2.08
Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation (1993) 2.04
Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res (1993) 1.98
Atrial natriuretic peptide and blood pressure in a population-based sample. Mayo Clin Proc (1995) 1.98
Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation (1991) 1.87
Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int (2007) 1.83
Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation (1993) 1.82
Natriuretic peptide system in human heart failure. Circulation (1993) 1.79
31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation (1992) 1.71
Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol (1984) 1.71
Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc (1992) 1.70
Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart (2009) 1.69
Macular pigment optical density measurement in autofluorescence imaging: comparison of one- and two-wavelength methods. Graefes Arch Clin Exp Ophthalmol (2006) 1.68
Assessing hypertension management in the community: trends of prevalence, detection, treatment, and control of hypertension in the MONICA Project, Augsburg 1984-1995. J Hum Hypertens (2001) 1.65
Trends in coronary risk factors in the WHO MONICA project. Int J Epidemiol (2001) 1.61
Disturbed calcium metabolism in subjects with elevated diastolic blood pressure. Clin Investig (1992) 1.61
Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res (1988) 1.58
Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest (1989) 1.57
Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation (1990) 1.57
Endothelin in human congestive heart failure. Circulation (1994) 1.56
Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation (1995) 1.55
Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol (1990) 1.55
Siblings of myocardial infarction patients are overlooked in primary prevention of cardiovascular disease. Eur Heart J (2001) 1.53
Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med (1990) 1.53
Prevalence of coronary blood flow reserve abnormalities among patients with nonobstructive coronary artery disease and chest pain. Mayo Clin Proc (1998) 1.53
Identification of atrial natriuretic factor within ventricular tissue in hamsters and humans with congestive heart failure. J Clin Invest (1988) 1.53
The D-allele of the ACE polymorphism is related to increased QT dispersion in 609 patients after myocardial infarction. Eur Heart J (2001) 1.52
Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol (1992) 1.50
Assessing the impact of classical risk factors on myocardial infarction by rate advancement periods. Am J Epidemiol (2000) 1.48
Effects of avertin versus xylazine-ketamine anesthesia on cardiac function in normal mice. Am J Physiol Heart Circ Physiol (2001) 1.44
Risk predictors in patients scheduled for percutaneous coronary revascularization. Catheter Cardiovasc Interv (1999) 1.43
Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res (1991) 1.43
Expression of atrial natriuretic factor in the human ventricle is independent of chamber dilation. J Am Coll Cardiol (1990) 1.41
Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction. Cardiovasc Res (1998) 1.41
Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol (1992) 1.41
Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation (1997) 1.40
Long-term effects of in-hospital cardiac rehabilitation on the cardiac risk profile. A case-control study in pairs of siblings with myocardial infarction. Eur Heart J (2001) 1.40
Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol (1998) 1.32
The cardiovascular risk factor profile in the study area Augsburg. Results from the first MONICA survey 1984/85. Acta Med Scand Suppl (1988) 1.31
Renal interstitial pressure and sodium excretion during renal vein constriction. Am J Physiol (1980) 1.31
Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J (1994) 1.30
Association of the 103I MC4R allele with decreased body mass in 7937 participants of two population based surveys. J Med Genet (2005) 1.29
Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system. Cardiovasc Res (1998) 1.29
Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc (2001) 1.29
Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol (2000) 1.28
Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens (1998) 1.28
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. Stat Med (2009) 1.27
Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol (1992) 1.27
Action of C-type natriuretic peptide in isolated canine arteries and veins. Am J Physiol (1993) 1.26
Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metab (2000) 1.25
Adenylate kinase-catalyzed phosphotransfer in the myocardium : increased contribution in heart failure. Circ Res (1999) 1.24
Failing energetics in failing hearts. Curr Cardiol Rep (2000) 1.24
Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol (1992) 1.23
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation (2001) 1.23
Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res (1991) 1.23
Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation (1994) 1.22
Adrenomedullin: potential in physiology and pathophysiology. Life Sci (2000) 1.22
Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol (1995) 1.21
Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators. J Am Coll Cardiol (1995) 1.20
The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians (1999) 1.20
Body composition and prevalence of left ventricular hypertrophy. Circulation (2000) 1.20
Changes in left ventricular structure and function in patients with white coat hypertension: cross sectional survey. BMJ (1998) 1.19
C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol (1993) 1.19
Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation (1995) 1.18
A single question about prior stroke versus a stroke questionnaire to assess stroke prevalence in populations. Neuroepidemiology (2000) 1.18
Physical activity at work and cardiovascular disease risk: results from the MONICA Augsburg study. Int J Epidemiol (1993) 1.16